294 related articles for article (PubMed ID: 9715276)
1. Point mutations in the tyrosine kinase domain release the oncogenic and metastatic potential of the Ron receptor.
Santoro MM; Penengo L; Minetto M; Orecchia S; Cilli M; Gaudino G
Oncogene; 1998 Aug; 17(6):741-9. PubMed ID: 9715276
[TBL] [Abstract][Full Text] [Related]
2. The Ron oncogenic activity induced by the MEN2B-like substitution overcomes the requirement for the multifunctional docking site.
Santoro MM; Penengo L; Orecchia S; Cilli M; Gaudino G
Oncogene; 2000 Oct; 19(45):5208-11. PubMed ID: 11064459
[TBL] [Abstract][Full Text] [Related]
3. Signalling of the Ret receptor tyrosine kinase through the c-Jun NH2-terminal protein kinases (JNKS): evidence for a divergence of the ERKs and JNKs pathways induced by Ret.
Chiariello M; Visconti R; Carlomagno F; Melillo RM; Bucci C; de Franciscis V; Fox GM; Jing S; Coso OA; Gutkind JS; Fusco A; Santoro M
Oncogene; 1998 May; 16(19):2435-45. PubMed ID: 9627110
[TBL] [Abstract][Full Text] [Related]
4. Point mutations and overexpression of Ron induce transformation, tumor formation, and metastasis.
Peace BE; Hughes MJ; Degen SJ; Waltz SE
Oncogene; 2001 Sep; 20(43):6142-51. PubMed ID: 11593422
[TBL] [Abstract][Full Text] [Related]
5. Increased in vivo phosphorylation of ret tyrosine 1062 is a potential pathogenetic mechanism of multiple endocrine neoplasia type 2B.
Salvatore D; Melillo RM; Monaco C; Visconti R; Fenzi G; Vecchio G; Fusco A; Santoro M
Cancer Res; 2001 Feb; 61(4):1426-31. PubMed ID: 11245446
[TBL] [Abstract][Full Text] [Related]
6. STK/RON receptor tyrosine kinase mediates both apoptotic and growth signals via the multifunctional docking site conserved among the HGF receptor family.
Iwama A; Yamaguchi N; Suda T
EMBO J; 1996 Nov; 15(21):5866-75. PubMed ID: 8918464
[TBL] [Abstract][Full Text] [Related]
7. MET(PRC) mutations in the Ron receptor result in upregulation of tyrosine kinase activity and acquisition of oncogenic potential.
Williams TA; Longati P; Pugliese L; Gual P; Bardelli A; Michieli P
J Cell Physiol; 1999 Dec; 181(3):507-14. PubMed ID: 10528237
[TBL] [Abstract][Full Text] [Related]
8. Oncogenic mutants of RON and MET receptor tyrosine kinases cause activation of the beta-catenin pathway.
Danilkovitch-Miagkova A; Miagkov A; Skeel A; Nakaigawa N; Zbar B; Leonard EJ
Mol Cell Biol; 2001 Sep; 21(17):5857-68. PubMed ID: 11486025
[TBL] [Abstract][Full Text] [Related]
9. Expression of multiple endocrine neoplasia 2B RET in neuroblastoma cells alters cell adhesion in vitro, enhances metastatic behavior in vivo, and activates Jun kinase.
Marshall GM; Peaston AE; Hocker JE; Smith SA; Hansford LM; Tobias V; Norris MD; Haber M; Smith DP; Lorenzo MJ; Ponder BA; Hancock JF
Cancer Res; 1997 Dec; 57(23):5399-405. PubMed ID: 9393766
[TBL] [Abstract][Full Text] [Related]
10. Identification of tyrosine residues that are essential for transforming activity of the ret proto-oncogene with MEN2A or MEN2B mutation.
Iwashita T; Asai N; Murakami H; Matsuyama M; Takahashi M
Oncogene; 1996 Feb; 12(3):481-7. PubMed ID: 8637703
[TBL] [Abstract][Full Text] [Related]
11. The multiple endocrine neoplasia type 2B point mutation alters long-term regulation and enhances the transforming capacity of the epidermal growth factor receptor.
Pandit SD; Donis-Keller H; Iwamoto T; Tomich JM; Pike LJ
J Biol Chem; 1996 Mar; 271(10):5850-8. PubMed ID: 8621456
[TBL] [Abstract][Full Text] [Related]
12. Nuclear factor-kappaB is constitutively active in C-cell carcinoma and required for RET-induced transformation.
Ludwig L; Kessler H; Wagner M; Hoang-Vu C; Dralle H; Adler G; Böhm BO; Schmid RM
Cancer Res; 2001 Jun; 61(11):4526-35. PubMed ID: 11389085
[TBL] [Abstract][Full Text] [Related]
13. Oncogenic activation of RET by two distinct FMTC mutations affecting the tyrosine kinase domain.
Pasini A; Geneste O; Legrand P; Schlumberger M; Rossel M; Fournier L; Rudkin BB; Schuffenecker I; Lenoir GM; Billaud M
Oncogene; 1997 Jul; 15(4):393-402. PubMed ID: 9242375
[TBL] [Abstract][Full Text] [Related]
14. Differential contribution of the ERK and JNK mitogen-activated protein kinase cascades to Ras transformation of HT1080 fibrosarcoma and DLD-1 colon carcinoma cells.
Plattner R; Gupta S; Khosravi-Far R; Sato KY; Perucho M; Der CJ; Stanbridge EJ
Oncogene; 1999 Mar; 18(10):1807-17. PubMed ID: 10086335
[TBL] [Abstract][Full Text] [Related]
15. Rit, a non-lipid-modified Ras-related protein, transforms NIH3T3 cells without activating the ERK, JNK, p38 MAPK or PI3K/Akt pathways.
Rusyn EV; Reynolds ER; Shao H; Grana TM; Chan TO; Andres DA; Cox AD
Oncogene; 2000 Sep; 19(41):4685-94. PubMed ID: 11032018
[TBL] [Abstract][Full Text] [Related]
16. Cross-talk between the proto-oncogenes Met and Ron.
Follenzi A; Bakovic S; Gual P; Stella MC; Longati P; Comoglio PM
Oncogene; 2000 Jun; 19(27):3041-9. PubMed ID: 10871856
[TBL] [Abstract][Full Text] [Related]
17. Characterization of Ret-Shc-Grb2 complex induced by GDNF, MEN 2A, and MEN 2B mutations.
Ohiwa M; Murakami H; Iwashita T; Asai N; Iwata Y; Imai T; Funahashi H; Takagi H; Takahashi M
Biochem Biophys Res Commun; 1997 Aug; 237(3):747-51. PubMed ID: 9299438
[TBL] [Abstract][Full Text] [Related]
18. Oncogenic signaling pathways activated by RON receptor tyrosine kinase.
Danilkovitch-Miagkova A
Curr Cancer Drug Targets; 2003 Feb; 3(1):31-40. PubMed ID: 12570659
[TBL] [Abstract][Full Text] [Related]
19. Glial cell line-derived neurotrophic factor differentially stimulates ret mutants associated with the multiple endocrine neoplasia type 2 syndromes and Hirschsprung's disease.
Carlomagno F; Melillo RM; Visconti R; Salvatore G; De Vita G; Lupoli G; Yu Y; Jing S; Vecchio G; Fusco A; Santoro M
Endocrinology; 1998 Aug; 139(8):3613-9. PubMed ID: 9681515
[TBL] [Abstract][Full Text] [Related]
20. Role of Dok1 in cell signaling mediated by RET tyrosine kinase.
Murakami H; Yamamura Y; Shimono Y; Kawai K; Kurokawa K; Takahashi M
J Biol Chem; 2002 Sep; 277(36):32781-90. PubMed ID: 12087092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
